CRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $99.00 at Barclays

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) had its price objective decreased by investment analysts at Barclays from $107.00 to $99.00 in a report issued on Tuesday, The Fly reports. Barclays‘s price target would indicate a potential upside of 129.01% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. Credit Suisse Group initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday, April 28th. They set a “neutral” rating and a $78.00 price target on the stock. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $171.00 to $168.00 in a report on Tuesday. Truist Financial restated a “buy” rating and issued a $220.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, February 16th. The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $179.00 to $87.00 and set a “neutral” rating on the stock in a report on Thursday, February 17th. Finally, Stifel Nicolaus cut their price target on shares of CRISPR Therapeutics to $64.00 in a research note on Wednesday, February 16th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has an average rating of “Buy” and a consensus target price of $124.64.

Shares of CRSP opened at $43.23 on Tuesday. CRISPR Therapeutics has a 52-week low of $43.05 and a 52-week high of $169.76. The firm’s fifty day moving average is $59.95 and its two-hundred day moving average is $69.03. The stock has a market cap of $3.35 billion, a PE ratio of 9.78 and a beta of 2.05.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($1.94) by ($0.38). The firm had revenue of $0.94 million for the quarter, compared to analyst estimates of $2.45 million. CRISPR Therapeutics had a net margin of 41.28% and a return on equity of 16.21%. The company’s revenue was up 74.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.51) EPS. On average, sell-side analysts predict that CRISPR Therapeutics will post -7.69 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in CRISPR Therapeutics in the first quarter valued at approximately $289,982,000. Nikko Asset Management Americas Inc. boosted its holdings in shares of CRISPR Therapeutics by 7.0% in the first quarter. Nikko Asset Management Americas Inc. now owns 4,619,747 shares of the company’s stock valued at $291,044,000 after acquiring an additional 300,276 shares during the period. Loomis Sayles & Co. L P boosted its holdings in shares of CRISPR Therapeutics by 42.1% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,316,123 shares of the company’s stock valued at $99,736,000 after acquiring an additional 390,209 shares during the period. BlackRock Inc. boosted its holdings in shares of CRISPR Therapeutics by 12.6% in the fourth quarter. BlackRock Inc. now owns 1,271,528 shares of the company’s stock valued at $96,358,000 after acquiring an additional 142,244 shares during the period. Finally, Bellevue Group AG boosted its holdings in shares of CRISPR Therapeutics by 0.8% in the third quarter. Bellevue Group AG now owns 974,684 shares of the company’s stock valued at $109,096,000 after acquiring an additional 7,800 shares during the period. 56.12% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories

The Fly logo

Analyst Recommendations for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.